New Insights into Therapeutic Targets for Cardiovascular Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Cardiovascular System".
Deadline for manuscript submissions: 15 May 2025 | Viewed by 4814
Special Issue Editors
2. Biomedical Sciences, College of Graduate Studies (CGS), Glendale, AZ 85308, USA
3. Department of Pharmaceutical Sciences, College of Pharmacy, Midwestern University, Glendale, AZ 23617, USA
Interests: nanomedicine; targeted delivery; cardiovascular/cancer/inflammatory therapeutics and diagnostics; nutraceuticals; pharmaceutical formulations; nano-bioengineering
Special Issues, Collections and Topics in MDPI journals
2. Biomedical Sciences, College of Graduate Studies (CGS),19555 N59th Avenue, Glendale, AZ 85308, USA
Interests: thrombospondin 1-associated pathophysiology and pharmacological strategy; new drug targets in GPCR-mediated signaling pathways; vascular and microvascular pathology and pharmacology; cardiovascular pharmacotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) continue to be the major cause of mortality and morbidity worldwide. The development of targeted therapeutics and diagnostics for CVDs has been a promising area of expanding research, aiming to improve treatment effectiveness and reduce adverse effects. New advances in molecular targets have provided exciting opportunities for the development of more precise diagnoses and effective treatment options.
Researchers have been uncovering novel molecular targets that play key roles in the pathogenesis of CVDs, paving the way for the development of innovative targeted therapies and offering more personalized and tailored interventions for patients. The discovery and validation of cardiac and vascular tissue biomarkers play a critical role in guiding the development and assessment of targeted drugs for CVDs. This Special Issue will explore the latest findings in the field of cardiovascular biomarkers, shedding light on their potential impact on clinical practice and patient outcomes.
Furthermore, nanomedicine has emerged as a rapidly evolving field with the potential to revolutionize the delivery of targeted therapies and imaging agents for cardiovascular diseases. The use of nanotechnology in drug delivery holds promise for enhancing the accuracy and efficacy of cardiovascular pharmacotherapy while also minimizing systemic side effects and improving patient compliance and health outcomes. The development of nanocarriers tailored for specific molecular target and/or tissue marker delivery within the cardiovascular system represents a cutting-edge approach with the potential to transform the future of CVD treatment and clinical outcomes.
Here, we invite scholars to contribute their valuable insights and novel research, both in the form of original research or review article submissions, on the various and latest insights into targeted drugs for cardiovascular diseases and the exciting advances in molecular targets, biomarkers, and nanomedicine. This Special Issue will emphasize the remarkable and promising innovation and progress in the pursuit of improved therapies for cardiovascular health.
Prof. Dr. Tamer Elbayoumi
Dr. Molly (Mingyi) Yao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiovascular disease prevention and treatment
- ischemic cardiomyopathies
- endothelium injury/damage
- cardiac remuscularization and repair
- cardiovascular/angiogenic targets and biomarkers
- targeted delivery platforms/systems/formulations
- precision nanomedicine
- targeted nano-theranostic applications
- localized and systemic administration
- safety and efficacy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
